Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
AstraZeneca
PMV Pharmaceuticals, Inc
Mayo Clinic
Alterome Therapeutics, Inc.
BeOne Medicines
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Genmab
Tizona Therapeutics, Inc
Canadian Cancer Trials Group
Eli Lilly and Company
City of Hope Medical Center
Eli Lilly and Company
Ocellaris Pharma, Inc.
Apollo Therapeutics Ltd
Innate Pharma
Novartis
OncoNano Medicine, Inc.
University Medical Center Groningen
NeoTX Therapeutics Ltd.
BicycleTx Limited
Bolt Biotherapeutics, Inc.
BicycleTx Limited
National Cancer Institute (NCI)
Nanobiotix
Rondo Therapeutics
ITM Oncologics GmbH
Janux Therapeutics
Maastricht University Medical Center
Institut Bergonié
Sichuan Baili Pharmaceutical Co., Ltd.
Scancell Ltd
Nurix Therapeutics, Inc.
A2 Biotherapeutics Inc.
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Cancer Research UK
Xencor, Inc.
NuCana plc
Incyte Corporation
Genentech, Inc.
NextPoint Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
UNICANCER
Monopar Therapeutics
Monopar Therapeutics